

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: PreveCeutical Medical Inc. (the "Issuer").

Trading Symbol: PREV

Number of Outstanding Listed Securities: 492,049,158

Date: June 4, 2020 (for the month ended May 31, 2020)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***During the month of May 2020, the Issuer continued its focus on developing its intellectual property assets and its protection.***

***On May 4, 2020, the Issuer announced that it was working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the “Program Extension”). The focus of the Program Extension will be on the expedited development of a cannabidiol (CBD) sol-gel, at GMP standards, to potentially reduce the possibility of coronavirus infections, including the current COVID-19. The Issuer is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. See news release dated [May 4, 2020](#) for further information.***

***On May 22, 2020, the Issuer announced that it has issued 95,600,253 common shares without par value in its capital (each, a “Share”) to various arm’s length creditors of the Company at a deemed issuance price of \$0.023 per Share. Further information is provided in Item 13 below and news release dated [May 22, 2020](#).***

2. Provide a general overview and discussion of the activities of management.

***During the month of May 2020, management’s activities consisted of general and administrative matters with focus on the research initiatives of the Issuer and potential partnering with biotech and pharmaceutical companies to further licensing of its technologies, debt conversion and debt settlement, and on completing the Q1 2020 condensed consolidated interim financial statements and MD&A. Management was also working on obtaining financing, including applying for Government funding.***

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable**

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not applicable**

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

***Please see the Issuer's Form 7 Monthly Progress Reports for the months ended November 2018 to April 2019, as well as for the month ended July 31, 2019. The legal proceedings set out in such reports, among others, are ongoing.***

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

***On May 20, 2020, the Issuer entered into a shares for debt settlement agreement with a supplier, Lotz & Co. (the "Supplier"), whereby the Company agreed to issue to the Supplier, and the Supplier agreed to accept 8,643,731 Shares (at a share price of \$0.023 per common share) as full and***

**final payment of the Company's indebtedness to the Supplier in the total amount of \$198,805.82 (the "Debt Settlement").**

**On May 20, 2020, the Issuer also entered into two assignment and assumption agreements, whereby certain arm's length assignees (the "Assignees") acquired all of Stephen Van Deventer and Kimberly Van Deventer's right, title, interests and obligations in and under a convertible credit facility agreement dated effective December 9, 2016, as amended, as to the aggregate principal amount of \$1,728,810.75 and the accrued interest thereon in the aggregate amount of \$271,189.25 (the "Assigned Amounts"). The Assignees have elected to convert the Assigned Amounts into an aggregate of 86,956,522 Shares (at a share price of \$0.023 per common share).**

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Common Shares	8,643,731	Common shares issued to Lotz & Co. to settle outstanding debt in the amount of \$198,805.82 at a price of \$0.023 per share	N/A
Common Shares	43,478,261	Common shares issued at the price of \$0.023 per share were issued in connection with a convertible note entered into by the Issuer and Jeffrey Ruskowsky.	N/A
Common Shares	43,478,261	Common shares issued at the price of \$0.023 per share were issued in connection with a convertible note entered into by the Issuer and Louis Lapointe	N/A

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**There were no loans to or by Related Persons during the month of May 2020.**

16. Provide details of any changes in directors, officers or committee members.

**Not applicable**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

***The production and distribution of health products are subject to federal, provincial and local laws, rules, regulations, and policies, and to international trade agreements, all of which provide a framework for the Issuer's operations. Regulatory amendments that may impact the Issuer include changes to food and drug laws, labelling laws, accounting standards, tax laws, competition laws and environmental laws, including***

***laws with respect to water rights and water treatment regulations and laws affecting the treatment of animals. Such changes can have an impact on the Issuer's financial results or increase its costs and liabilities. Such changes would also affect all health products and would not disproportionately harm the Issuer relative to the health product industry.***

***The unprecedented challenges from the Covid-19 pandemic has negatively impacted the investment market and the retail market for health related products. This will adversely impact the Issuer's ability to raise more capital and to successfully commercialize or promote current or future products while the effects of the pandemic are in effect. It is currently unknown with certainty how long the current global pandemic will last.***

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 4, 2020

Shabira Rajan  
Name of Director or Senior Officer

"Shabira Rajan" signed  
Signature

CFO, Controller and Corporate Secretary  
Official Capacity

<b>Issuer Details</b> Name of Issuer <b>PreveCeutical Medical Inc.</b>	For Month End <b>May 2020</b>	Date of Report YY/MM/D <b>20/06/04</b>
Issuer Address 1177 West Hastings Street, Suite 2200		
City/Province/Postal Code <b>Vancouver, British Columbia, V6E 2K3</b>	Issuer Fax No. <b>NA</b>	Issuer Telephone No. <b>604-416-7777</b>
Contact Name <b>Shabira Rajan</b>	Contact Position <b>CFO, Controller and Corporate Secretary</b>	Contact Telephone No. <b>604-782-6300</b>
Contact Email Address <a href="mailto:shabira@preveceutical.com">shabira@preveceutical.com</a>	Web Site Address <a href="http://www.preveceutical.com">www.preveceutical.com</a>	